News for Providers
Top stories summarized by our editors
10/15/2018

Novartis has launched Novartis Biome, a digital health innovation lab network, and a set of worldwide innovation challenges it calls the HealthX World Series. "The idea is to give the health tech ecosystem a boost and clear 'on-ramp' to work with Novartis," said Robin Roberts, head of innovation and strategy.

Full Story:
PharmaPhorum (UK)
More Summaries:
Novartis
10/15/2018

Although most hospitals are using an EHR system, interoperability is still an obstacle, with nearly 75% of hospitals using more than 10 disparate outpatient vendors, and only 2% of hospitals using a single vendor at all affiliated practices, according to HIMSS Analytics' State of the Market 2018 report. Researchers also found that 45.3% of hospitals are still learning about blockchain and have not implemented any related programs within their organizations, while 65% reported currently using cloud or cloud services, and 50% of respondents provide telehealth services.

More Summaries:
HIMSS Analytics, HIMSS
10/15/2018

A panel at the MedCity Engage conference in San Diego on Nov. 6 will delve into the methods companies are undertaking to improve price transparency and the potential impact that price transparency could have on lowering larger healthcare costs. "That consumer anxiety when we get sick is exacerbated by not knowing how it will cost is unacceptable," said urgent care company Solv CEO and co-founder Heather Fernandez.

Full Story:
MedCity News
10/15/2018

Women who took aspirin daily were 10% less likely to develop ovarian cancer, compared with those who didn't, researchers reported in the Journal of the National Cancer Institute. Another study in The Lancet Oncology showed up to 30% improved survival among women with ovarian cancer who received aspirin or nonaspirin nonsteroidal anti-inflammatory drugs, such as naproxen and ibuprofen, after diagnosis.

Full Story:
Cure Today
10/15/2018

A study published in JAMA Network Open found that from 2007 to 2016, the FDA identified 776 dietary supplements that contained pharmaceuticals, but only 46.4% were linked to a voluntary recall. The most common adulterated supplements were those for sexual enhancement, weight loss and muscle building.

Full Story:
The Scientist online
More Summaries:
FDA
10/15/2018

Dutch researchers examined dynamic F-18 flutemetamol PET scans from older adults with normal cognition and found that images quantified using nondisplaceable binding potential yielded "good" interreader agreement, compared with "moderate" agreement using standard uptake value ratio imaging. The findings in the Journal of Nuclear Medicine also showed reader discordance in only 15 cases with BPND images, compared with 35 SUVR cases, 91% of which were negative based on semiquantitative measurements.

Full Story:
Health Imaging online
10/15/2018

A breakthrough computer model combining brain biomechanics and biochemistry that was developed by researchers at Stevens Institute of Technology in New Jersey was able to map and simulate how toxic proteins associated with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis spread in the brain. The findings were published in the journal Physical Review Letters.

Full Story:
Newsweek
10/15/2018

Young healthy mice on a ketogenic diet had significantly better neurovascular integrity involved in cognitive ability, as well as significantly improved removal of amyloid-beta plaques associated with Alzheimer's disease, compared with those that were given a regular diet, according to a study in Frontiers in Aging Neuroscience. Researchers also found better gut microbiome balance and reduced body weight and blood glucose levels among those in the ketogenic diet group.

More Summaries:
Alzheimer's disease
10/15/2018

Mediso Medical Imaging Systems and the National Physical Laboratory in the UK have entered a research collaboration that will enable NPL to use Mediso's AnyScan SPECT/CT/PET system in developing unique measurement abilities and provide the world's first triple-modality scanner directly calibrated using primary radioactivity standards. Mediso will apply the study's findings to its imaging products, said managing director Istvan Bagamery.

Full Story:
PharmaBiz (India)
10/15/2018

Israeli researchers found that bypassing agents used to treat hemophilia A patients, whether as a single or combination therapy, had the potential to become an alternative therapy option for pediatric hemophilia B patients with factor IX inhibitors, based on data from a nine-year follow-up study of three pediatric patients who did not experience severe adverse events or thrombosis throughout the study period after being treated with increasing concentrations of recombinant activated factor VII or factor VIII inhibitor bypassing activity. The findings were published in the journal Pediatric Blood & Cancer.

Full Story:
Hemophilia News Today